Heron Therapeutics, Inc.
HRTX
$0.41
$0.001.16%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -407.82% | -180.64% | -260.87% | 74.22% | 183.39% |
| Total Depreciation and Amortization | -3.99% | -7.57% | 5.85% | -4.68% | -20.03% |
| Total Amortization of Deferred Charges | 4.27% | -32.00% | -48.01% | 43.06% | 50.71% |
| Total Other Non-Cash Items | 29.28% | 3.76% | 378.05% | -63.03% | -24.46% |
| Change in Net Operating Assets | 120.63% | 50.58% | -14.43% | -250.41% | -43.31% |
| Cash from Operations | 82.64% | 22.04% | -60.52% | -136.06% | 6.79% |
| Capital Expenditure | -258.72% | 100.00% | 100.00% | 67.35% | -- |
| Sale of Property, Plant, and Equipment | -- | -40.74% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -123.42% | -145.49% | 168.78% | 180.48% | 83.10% |
| Cash from Investing | -141.31% | -147.78% | 198.69% | 258.11% | 77.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 5,761.11% | 218.90% | 481.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -1,906.40% | -21.34% | -- |
| Cash from Financing | -179.69% | -48.23% | 95,350.00% | 58.74% | 481.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.27% | -23,740.98% | 261.01% | -33.38% | 20.59% |